Clinical remission rate and drug withdrawal status in articular juvenile idiopathic arthritis

Table 5 Cases of bDMARD withdrawal

	RF − PJIA (n = 2 [50%])	OJIA (n = 2 [29%])
Concomitant use of csDMARDs at withdrawal of bDMARDs, n (%)	0 (0%)	1 (50%)
History of csDMARDs use at withdrawal of bDMARDs, n (%)	2 (100%)^a	1 (50%)^a
CRM duration before drug withdrawal (months)
Case 1	65	32
Case 2	34	33
Type of bDMARD withdrawn, n
Adalimumab	1^b	0
Tocilizumab	1^b	2^c
Method of drug withdrawal, n
Immediate discontinuation	2	1
Prolonged dosing interval	0	1
With flare, n (%)	2 (100%)	1 (50%)
Time to flare (months)
Case 1	7	23
Case 2	5	-
Response after relapse, n
Switch to other bDMARDs	1^d	0
Resumed same bDMARDs	1	1
Disease activity at the end of observation, n
Active disease	0	1
CRM	2	1 (no medication)^e

bDMARD biological disease-modifying antirheumatic drug, CRM clinical remission on medication, csDMARD conventional synthetic disease-modifying antirheumatic drug, OJIA oligoarticular juvenile idiopathic arthritis, PJIA polyarticular juvenile idiopathic arthritis, RF rheumatoid factor
^aDiscontinuation due to adverse events
^bSubcutaneous injection
^cIntravenous injection
^dChanged from adalimumab to tocilizumab
^eThis patient was withdrawn from all medications; however, the criteria for CR were not achieved by the conclusion of the observation period. This patient initially discontinued TCZ and sustained CRM for one year on MTX monotherapy, after which MTX was also discontinued

ISSN: 1546-0096